PUBLIC COMPANY
save$ANNXAnnexon, Inc.
$ANNX4.2300+2.42%Brisbane, CA, USupdated 20h ago
community read0 votes
pipeline
2
marketed
0
phase 3
2
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase3A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
- phase3An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
- phase3Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
- phase2Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
- phase1Dose Study of ANX1502 in Healthy Volunteers
- phase1A Study of ANX009 in Adult Participants With Lupus Nephritis
- phase2A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
- phase1Single Ascending Dose Study of ANX105
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 10, 26BUYCarson William H.· $50K↗
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 55m ago
Found something off?
comments(0)
5-min edit window · permanent after that